All In Biotech

Drug Trial Radar · NCT05667649

Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease

Ph 1, Open-Label Safety Study of Escalating Doses of Intracerebroventricular Injections of Ex Vivo Expanded, Autologous ADSCs in Participants With Mild-Moderate AD Whose Treatment is Not Addressed Adequately by Available Therapy

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

7

Actual

Start

Aug 14, 2023

Primary completion

Jun 25, 2026

Study completion Jun 25, 2026

Sponsor

Lead sponsor
Regeneration Biomedical, Inc.Industry
Sponsor type
Industry
First posted
Dec 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a research study to evaluate the safety of an investigational autologous cell product obtained from participant's own adipose tissue as a possible treatment for Alzheimer disease.

Conditions

  • Alzheimer Disease

Interventions

  • RB-ADSCBiological

    Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (ADSCs)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The safety of RB-ADSC treatment in study participants with ADTime frame: up to 28 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.